Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat rollover extension study after prior Novartis panobinostat trial
NL-OMON40870Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in Nonhematologic neoplasms and cancer, sponsored by Novartis. Primary endpoint: Continued access to panobinostat. Started Jun 2014; status: active, not recruiting.
02
Drugs
panobinostat
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on NL-OMON40870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40870.